HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Metastatic Breast Cancer
Interventions
DIAGNOSTIC_TEST

68Ga-NOTA-ABSCINT-HER2 PET/CT

68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.

Trial Locations (6)

1070

RECRUITING

AZ Delta CHIREC, Brussels

RECRUITING

Cliniques Universitaires Saint-Luc, Brussels

RECRUITING

Free University Brussels (VUB), Brussels

RECRUITING

Institut Jules Bordet, Brussels

9300

RECRUITING

OLV Aalst, Aalst

Unknown

RECRUITING

University Hospital Gasthuisberg, Leuven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abscint NV/SA

INDUSTRY

NCT06369831 - HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 | Biotech Hunter | Biotech Hunter